Avenue therapeutics reports third quarter 2019 financial results and recent corporate highlights

Avenue therapeutics reports third quarter 2019 financial results and recent corporate highlights.q3 loss per share $0.14.q3 earnings per share estimate $-0.28 -- refinitiv ibes data.qtrly cash and cash equivalents and short-term investments totaled $13.7 million, compared to $15.5 million at june 30, 2019.net loss for three months ended september 30, 2019 was $0.14 per share.avenue therapeutics- looking ahead, on track to submit a new drug application for iv tramadol to u.s. fda by year-end 2019.
ATXI Ratings Summary
ATXI Quant Ranking